BG105302A - Means for improving cognition - Google Patents

Means for improving cognition

Info

Publication number
BG105302A
BG105302A BG105302A BG10530201A BG105302A BG 105302 A BG105302 A BG 105302A BG 105302 A BG105302 A BG 105302A BG 10530201 A BG10530201 A BG 10530201A BG 105302 A BG105302 A BG 105302A
Authority
BG
Bulgaria
Prior art keywords
improving cognition
acetylcholinesterase
alzheimer
inhibitor
administered
Prior art date
Application number
BG105302A
Other languages
Bulgarian (bg)
English (en)
Inventor
NIJS Paul Leonce DE
Wim Louis PARYS
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG105302A publication Critical patent/BG105302A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
BG105302A 1998-10-16 2001-03-01 Means for improving cognition BG105302A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203454 1998-10-16
PCT/EP1999/007804 WO2000023057A2 (en) 1998-10-16 1999-10-12 Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition

Publications (1)

Publication Number Publication Date
BG105302A true BG105302A (en) 2001-11-30

Family

ID=8234219

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105302A BG105302A (en) 1998-10-16 2001-03-01 Means for improving cognition

Country Status (20)

Country Link
EP (1) EP1121131A2 (id)
JP (1) JP2002527469A (id)
KR (1) KR20010072878A (id)
CN (1) CN1367697A (id)
AU (1) AU6472799A (id)
BG (1) BG105302A (id)
BR (1) BR9914419A (id)
CA (1) CA2345767A1 (id)
EE (1) EE200100136A (id)
HK (1) HK1039745A1 (id)
HR (1) HRP20010262A2 (id)
HU (1) HUP0103781A3 (id)
ID (1) ID28441A (id)
IL (1) IL142588A0 (id)
NO (1) NO20011403L (id)
PL (1) PL348107A1 (id)
SK (1) SK4592001A3 (id)
TR (1) TR200101082T2 (id)
WO (1) WO2000023057A2 (id)
ZA (1) ZA200103081B (id)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
BRPI0213564B8 (pt) 2001-10-30 2021-05-25 Novartis Ag formulação depósito e micropartícula compreendendo iloperidona e polímero poli(d,l-lactídeo-co-glicolídeo), e processo para preparação da referida micropartícula
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
WO2006065233A1 (en) * 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
MX2007008642A (es) * 2007-07-16 2009-02-25 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias.
AU2011215870B2 (en) 2010-02-09 2016-01-28 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
WO1992020327A1 (en) * 1991-05-14 1992-11-26 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
JP4640888B2 (ja) * 1997-08-11 2011-03-02 ザ ユニヴァーシティー オブ サウス フロリダ 神経精神性疾患用ニコチンアンタゴニスト
EP1073432B1 (en) * 1998-04-14 2007-08-15 The General Hospital Corporation Use of d-serine or d-alanine for treating schizophrenia

Also Published As

Publication number Publication date
WO2000023057A3 (en) 2000-07-27
TR200101082T2 (tr) 2001-09-21
HRP20010262A2 (en) 2002-06-30
HUP0103781A2 (hu) 2002-03-28
HK1039745A1 (zh) 2002-05-10
NO20011403D0 (no) 2001-03-20
CN1367697A (zh) 2002-09-04
WO2000023057A2 (en) 2000-04-27
HUP0103781A3 (en) 2003-09-29
AU6472799A (en) 2000-05-08
CA2345767A1 (en) 2000-04-27
BR9914419A (pt) 2001-06-26
NO20011403L (no) 2001-03-20
EP1121131A2 (en) 2001-08-08
SK4592001A3 (en) 2001-12-03
KR20010072878A (ko) 2001-07-31
IL142588A0 (en) 2002-03-10
PL348107A1 (en) 2002-05-06
ID28441A (id) 2001-05-24
ZA200103081B (en) 2002-07-12
JP2002527469A (ja) 2002-08-27
EE200100136A (et) 2002-06-17

Similar Documents

Publication Publication Date Title
BG105302A (en) Means for improving cognition
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
BR0008059A (pt) Composições de valdecoxib
IL119989A0 (en) Pharmaceutical compositions for oral treatment of multiple sclerosis
EP1040830A4 (en) MEDICINE FOR NEURODEGENERATIVE DISEASES
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
AU2002307049A1 (en) Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
ATE240115T1 (de) Zusammensetzung zur vorbeugung und/oder behandlung der atherosklerose
BG105256A (en) Muscarinic agonists and antagonists
CA2284551A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
IL149134A0 (en) Pharmaceutical compositions containing tofisopam
IL124091A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
IL159241A0 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
AU4568400A (en) Sphingomyelinase inhibitor
GEP20043377B (en) Pharmaceutical Complex
WO2002024727A3 (en) New inhibitors of iapp fibril formation and uses thereof
BR0005319A (pt) Tratamento combinado para depressão e ansiedade